Manufacturer of Controlled Substances; Notice of Registration; Pharmagra Labs, Inc., 34073 [2012-13917]

Download as PDF Federal Register / Vol. 77, No. 111 / Friday, June 8, 2012 / Notices Morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for conversion and sale to dosage form manufacturers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 7, 2012. Dated: May 31, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control. Drug Enforcement Administration. [FR Doc. 2012–13919 Filed 6–7–12; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; S&B Pharma, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 4, 2012, S&B Pharma Inc., 405 South Motor Avenue, Azusa, California 91702–3232, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule mstockstill on DSK4VPTVN1PROD with NOTICES Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Methamphetamine (1105) ............ Pentobarbital (2270) ..................... Nabilone (7379) ............................ I I II II II The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement VerDate Mar<15>2010 16:23 Jun 07, 2012 Jkt 226001 Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 7, 2012. Dated: May 31, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–13918 Filed 6–7–12; 8:45 am] BILLING CODE 4410–09–P 34073 OFFICE OF MANAGEMENT AND BUDGET Office of Federal Procurement Policy Value Engineering Office of Federal Procurement Policy, Office of Management and Budget. AGENCY: Proposed revision to Office of Management and Budget Circular No. A–131, ‘‘Value Engineering’’. ACTION: The Office of Federal Procurement Policy (OFPP) in the Office of Management and Budget (OMB) is proposing to revise OMB Circular A– 131, Value Engineering, to update and reinforce policies associated with the consideration and use of Value Engineering (VE). VE is an effective technique for cutting waste and inefficiency—helping Federal agencies save billions of dollars in program and acquisition costs, improve performance, enhance quality, and foster the use of innovation. The proposed revisions are designed to ensure that the Federal Government has the capabilities and tools to consider and apply VE techniques to the maximum extent appropriate. SUMMARY: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Pharmagra Labs, Inc. By Notice dated January 30, 2012, and published in the Federal Register on February 6, 2012, 77 FR 5846, Pharmagra Labs Inc., 158 McLean Road, Brevard, North Carolina 28712, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Pentobarbital (2270), a basic class of controlled substance in schedule II. The company plans to manufacture the listed substance for analytical research and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Pharmagra Labs, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Pharmagra Labs, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 31, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Interested parties should submit comments in writing to the address below on or before August 7, 2012. DATES: Comments may be submitted by any of the following methods: • Online at: https:// www.regulations.gov. • Facsimile: 202–395–5105. • Mail: Office of Federal Procurement Policy, ATTN: Curtina Smith, New Executive Office Building, Room 9013, 725 17th Street NW., Washington, DC 20503. Instructions: Please submit comments only and cite ‘‘Proposed Revision to OMB Circular A–131’’ in all correspondence. All comments received will be posted, without change or redaction, to www.regulations.gov, so commenters should not include information that they do not wish to be posted (for example because they consider it personal or business confidential). ADDRESSES: FOR FURTHER INFORMATION CONTACT: [FR Doc. 2012–13917 Filed 6–7–12; 8:45 am] Curtina Smith, OFPP, csmith@omb.eop.gov. Availability: Copies of the proposed revision to OMB Circular A–131 are available on OMB’s Web site at https://www.whitehouse.gov/ omb/circulars_default/. BILLING CODE 4410–09–P SUPPLEMENTARY INFORMATION: PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 E:\FR\FM\08JNN1.SGM 08JNN1

Agencies

[Federal Register Volume 77, Number 111 (Friday, June 8, 2012)]
[Notices]
[Page 34073]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-13917]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Pharmagra Labs, Inc.

    By Notice dated January 30, 2012, and published in the Federal 
Register on February 6, 2012, 77 FR 5846, Pharmagra Labs Inc., 158 
McLean Road, Brevard, North Carolina 28712, made application by renewal 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Pentobarbital (2270), a basic class of controlled 
substance in schedule II.
    The company plans to manufacture the listed substance for 
analytical research and clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of Pharmagra Labs, Inc. to manufacture the listed basic class of 
controlled substance is consistent with the public interest at this 
time. DEA has investigated Pharmagra Labs, Inc. to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic class of controlled substance listed.

     Dated: May 31, 2012.
 Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2012-13917 Filed 6-7-12; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.